Citius Pharmaceuticals (NASDAQ:CTXR) Given “Hold” Rating at D. Boral Capital

Citius Pharmaceuticals (NASDAQ:CTXR)‘s stock had its “hold” rating reissued by D. Boral Capital in a research note issued to investors on Friday,Benzinga reports.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

Citius Pharmaceuticals Price Performance

Shares of Citius Pharmaceuticals stock opened at $0.20 on Friday. The stock’s 50 day simple moving average is $0.40 and its 200-day simple moving average is $0.58. The stock has a market cap of $36.63 million, a P/E ratio of -0.56 and a beta of 1.66. Citius Pharmaceuticals has a 1-year low of $0.11 and a 1-year high of $1.07.

Citius Pharmaceuticals’s stock is scheduled to reverse split on Tuesday, November 26th. The 1-25 reverse split was announced on Friday, November 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, November 25th.

Institutional Trading of Citius Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Armistice Capital LLC purchased a new stake in Citius Pharmaceuticals in the 2nd quarter valued at about $5,928,000. Geode Capital Management LLC lifted its holdings in Citius Pharmaceuticals by 14.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock worth $941,000 after buying an additional 232,656 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Citius Pharmaceuticals in the second quarter valued at $118,000. Cubist Systematic Strategies LLC purchased a new position in shares of Citius Pharmaceuticals in the 2nd quarter valued at about $69,000. Finally, Vanguard Group Inc. lifted its stake in Citius Pharmaceuticals by 1.5% in the first quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock worth $6,286,000 after acquiring an additional 104,889 shares during the last quarter. Institutional investors and hedge funds own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.